Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | ZELLA 101: alvocidib for newly diagnosed AML

Joshua Zeidner • 8 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia Alvocidib Cytarabine Daunorubicin Mitoxantrone
ZELLA 101

Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, discusses results from the Phase I ZELLA 101 study of alvocidib, a CDK9 kinase inhibitor, for newly diagnosed acute myeloid leukemia (AML) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Joshua Zeidner

5:13
Phase II trial of pembrolizumab prior to allo-SCT in AML
Joshua Zeidner • 25 Nov 2020
4:57
The impact of pevonedistat on patient-reported outcomes in the P-2001 study
Joshua Zeidner • 25 Nov 2020
5:08
Zella 201: alvocidib-based regimens in MCL-1 dependent high-risk AML
Joshua Zeidner • 25 Nov 2020
6:11
Immunomodulation with pomalidomide in AML and high-risk MDS
Joshua Zeidner • 8 Jun 2020

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals